Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma

Annals of Hematology

Volumn 89, Issue 9, 2010, Pages 897-904

  Hirakawa, Tsuneaki ^a   Yamaguchi, Hiroki ^a   Yokose, Norio ^a   Gomi, Seiji ^b   Inokuchi, Koiti ^a   Dan, Kazuo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b Yokohama Minami Kyosai Hospital   (Japan)

Author keywords

CHOP therapy; Diffuse large B cell lymphoma; Granulocyte colony stimulating factor; Relative dose intensity; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PIRARUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; AGING; ARTICLE; CANCER SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; VINCRISTINE;

EID: 77955660165     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0956-7     Document Type: Article

References (28)

1. LM Morton SS Wang SS Devesa, et al. 2006 Lymphoma incidence patterns by WHO subtype in the United States Blood 107 1 265 276 10.1182/blood-2005-06-2508 1:CAS:528:DC%2BD28XhsVGlsg%3D%3D 16150940 (Pubitemid 43053551)
2. R Aoki K Karube Y Sugita, et al. 2008 Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006 Pathol Int 58 3 174 182 10.1111/j.1440-1827.2007.02207.x 18251781 (Pubitemid 351190172)
3. JM Vose BK Link ML Grossbard, et al. 2001 Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol 19 2 389 397 1:CAS:528: DC%2BD3MXhtVekt7o%3D 11208830
4. B Coiffier E Lepage J Briere, et al. 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 4 235 242 10.1056/NEJMoa011795 1:CAS:528: DC%2BD38XmslGgsw%3D%3D 11807147 (Pubitemid 34438862)
5. LH Sehn J Donaldson M Chhanabhai, et al. 2005 Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia J Clin Oncol 23 22 5027 5033 10.1200/JCO.2005.09.137 1:CAS:528:DC%2BD2MXpsFWmtLs%3D 15955905 (Pubitemid 46224009)
6. LH Sehn B Berry M Chhanabhai, et al. 2007 The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood 109 5 1857 1861 10.1182/blood-2006-08-038257 1:CAS:528:DC%2BD2sXjtFeqt7g%3D 17105812 (Pubitemid 46348180)
7. YH Park JJ Lee MH Ryu, et al. 2006 Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients Ann Hematol 85 4 257 262 10.1007/s00277-005-0060-6 1:STN:280:DC%2BD287gvVWguw%3D%3D 16416337
8. DW Blayney ML LeBlanc T Grogan, et al. 2003 Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349) J Clin Oncol 21 13 2457 2459 10.1200/JCO.2003.06.137 (Pubitemid 46606326)
9. M Pfreundschuh L Truemper M Kloess, et al. 2004 Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL Blood 104 3 634 641 10.1182/blood-2003-06-2095 1:CAS:528:DC%2BD2cXmtlCkt7Y%3D 15016643 (Pubitemid 38970554)
10. K Tobinai T Hotta 2004 Clinical trials for malignant lymphoma in Japan Jpn J Clin Oncol 34 7 369 378 10.1093/jjco/hyh060 15342663 (Pubitemid 43115299)
11. RI Fisher ER Gaynor S Dahlberg, et al. 1993 Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 328 14 1002 1006 10.1056/NEJM199304083281404 1:STN:280:DyaK3s7ps1Kmtg%3D%3D 7680764 (Pubitemid 23095683)
12. RI Fisher ER Gaynor S Dahlberg, et al. 1994 A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study Ann Oncol 5 Suppl 2 91 95 7515652
13. MR Sertoli G Santini T Chisesi, et al. 1994 MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group J Clin Oncol 12 7 1366 1374 1:STN:280:DyaK2c3ptlSlsA%3D%3D 7517442
14. LI Gordon J Andersen J Colgan, et al. 1995 Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study Cancer 75 3 865 873 10.1002/1097-0142(19950201)75:3<865::AID-CNCR2820750319>3.0.CO;2-Z 1:STN:280:DyaK2M7ivFSntA%3D%3D 7530168
15. R Epelbaum N Haim M Ben-Shahar, et al. 1988 Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma Isr J Med Sci 24 9-10 533 538 1:STN:280:DyaL1M%2FnvFCisA%3D%3D 3060443
16. DO Dixon B Neilan SE Jones, et al. 1986 Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience J Clin Oncol 4 3 295 305 1:STN:280:DyaL287kt1yqtw%3D%3D 3512783
17. LW Kwak J Halpern RA Olshen SJ Horning 1990 Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis J Clin Oncol 8 6 963 977 1:STN:280: DyaK3c3ntV2hsg%3D%3D 2348230
18. R Epelbaum D Faraggi Y Ben-Arie, et al. 1990 Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables Cancer 66 6 1124 1129 10.1002/1097-0142(19900915)66:6<1124::AID- CNCR2820660608>3.0.CO;2-T 1:STN:280:DyaK3czotFKgsQ%3D%3D 2205353
19. E Lepage C Gisselbrecht C Haioun, et al. 1993 Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte) Ann Oncol 4 8 651 656 1:STN:280:DyaK2c%2FlvFOqsQ%3D%3D 7694634
20. A Bosly D Bron A Van Hoof, et al. 2008 Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP Ann Hematol 87 4 277 283 10.1007/s00277-007-0399-y 1:CAS:528:DC%2BD1cXjsVGjtLo%3D 17952688 (Pubitemid 351445288)
21. R Pettengell M Schwenkglenks A Bosly 2008 Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy Ann Hematol 87 5 429 430 10.1007/s00277-008-0447-2 1:STN:280: DC%2BD1czgvFektg%3D%3D 18299833
22. GH Lyman DC Dale J Friedberg, et al. 2004 Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study J Clin Oncol 22 21 4302 4311 10.1200/JCO.2004.03.213 1:CAS:528: DC%2BD2cXhtVKju7fO 15381684 (Pubitemid 41185151)
23. H Tsurumi T Hara N Goto, et al. 2007 A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma Hematol Oncol 25 3 107 114 10.1002/hon.815 1:CAS:528:DC%2BD2sXht1SrsbzP 17457949 (Pubitemid 47507877)
24. T Hara H Tsurumi N Goto, et al. 2009 Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma J Cancer Res Clin Oncol Doi: 136 65 70 10.1007/s00432-009-0637-x
25. WT Hughes D Armstrong GP Bodey, et al. 2002 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer Clin Infect Dis 34 6 730 751 10.1086/339215 11850858 (Pubitemid 34194843)
26. The International Non-Hodgkin's Lymphoma Prognostic Factors Project 1993 A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 329 14 987 994 10.1056/NEJM199309303291402 (Pubitemid 23307906)
27. Y Terada H Nakamae R Aimoto, et al. 2009 Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma J Exp Clin Cancer Res 28 116 10.1186/1756-9966-28-116 19689822
28. TJ Smith J Khatcheressian GH Lyman, et al. 2006 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 19 3187 3205 10.1200/JCO.2006.06.4451 1:CAS:528:DC%2BD28XnslKhsLo%3D 16682719 (Pubitemid 46638957)